FDA Grants Rybrevant Faspro Accelerated Approval for Head and Neck Squamous Cell Carcinoma M. Alexander Otto, MMSc-PA

https://www.medscape.com/viewarticle/fda-grants-rybrevant-faspro-accelerated-approval-head-and-2026a10016jm?src= The FDA has granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase, Johnson & Johnson) for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.